Dark

Check out our API

AERI
Aerie Pharmaceuticals, Inc.
stock NASDAQ

Inactive

Nov 18, 2022

15.25USD+0.066%(+0.01)1,215,184

Pre-market

0.00USD-100.000%(-15.24)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Dec 22, 2021

04:01PM EST Aerie Pharmaceuticals Reports Inducement Grant to Chief Executive Officer Under Nasdaq Listing Rule 5635(c)(4) Business Wire

Dec 16, 2021

06:34AM EST Aerie Pharma Appoints Raj Kannan As CEO RTTNews

06:33AM EST Aerie Pharmaceuticals Appoints Raj Kannan As Chief Executive Officer Benzinga

Dec 7, 2021

07:44AM EST Aerie Inks Licensing Pact With Santen for Rhopressa And Rocklatan In Europe Benzinga

04:45AM EST Aerie Pharmaceuticals Announced Exclusive License Agreement With Santen for Rhopressa and Rocklatan in Europe and Several Other Regions; Aeries to Receive Upfront Payment of $88M, Various Milestones of up to $77M, Plus Additional Consideration in Excess of 25% of Products' Net Sales Benzinga

02:00AM EST Aerie Concludes Exclusive License Agreement With Santen for Rhopressa(r) and Rocklatan(r) in Europe and Several Other Regions Business Wire

Nov 9, 2021

04:30PM EST Aerie Pharmaceuticals to Participate in Upcoming Investor Conferences Business Wire

Nov 5, 2021

09:38AM EDT Needham Maintains Buy on Aerie Pharmaceuticals, Lowers Price Target to $22 Benzinga

09:23AM EDT Aerie Pharmaceuticals Q3 EPS $(0.86) Misses $(0.62) Estimate, Sales $29.30M Beat $28.89M Estimate Benzinga

Nov 4, 2021

04:01PM EDT Aerie Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update Business Wire

08:19AM EDT The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO Benzinga

05:00AM EDT Earnings Scheduled For November 4, 2021 Benzinga

Oct 31, 2021

02:24PM EDT The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline Benzinga

Oct 28, 2021

07:30AM EDT Aerie Pharmaceuticals to Announce Third Quarter 2021 Financial Results and Host Conference Call on Thursday, November 4, 2021 Business Wire

Oct 21, 2021

04:02PM EDT Aerie Pharmaceuticals Announces Presentation At The Ophthalmology Innovation Summit Glaucoma Innovation Showcase Benzinga

Oct 19, 2021

04:14PM EDT Aerie Pharma 8-K Shows Interim CFO Christopher Staten Resigned; Co. Is Conducting A Search To Find A Replacement Benzinga

Oct 12, 2021

08:13AM EDT The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology Benzinga

06:58AM EDT Aerie Pharmaceuticals Inc. (AERI) said it has successfully completed its first phase 3 clinical trial in Japan which further confirmed that netarsudil ophthalmic solution 0.02% achieves impressive intraocular pressure or IOP-lowering efficacy in a patient population with lower baseline pressures. RTTNews

06:35AM EDT Aerie Pharma Reports Positive Phase 3 Topline Results For Netarsudil Ophthalmic Solution 0.02% Clinical Trial In Japan RTTNews

06:32AM EDT Aerie Pharmaceuticals Announces Phase 3 Topline Results For Netarsudil Ophthalmic Solution 0.02% Clinical Trial In Japan; Netarsudil Ophthalmic Solution 0.02% Once Daily Demonstrated Superiority To Ripasudil 0.4% Twice Daily Benzinga

06:30AM EDT Aerie Pharmaceuticals Announces Positive Phase 3 Topline Results for Netarsudil Ophthalmic Solution 0.02% Clinical Trial in Japan Business Wire

Oct 10, 2021

11:59AM EDT The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations and IPOs Take Center Stage Benzinga

Oct 7, 2021

04:02PM EDT Aerie Pharmaceuticals Announces Presentation At The Ophthalmology Innovation Summit Retina Innovation Showcase Benzinga

Oct 6, 2021

07:36AM EDT Aerie To Present Results From AR-1105 Phase 2 Trial In Patients With Macular Edema Due To Retinal Vein Occlusion RTTNews

07:30AM EDT Aerie Pharmaceuticals Announces Presentation at the 39th Annual Scientific Meeting of the American Society of Retina Specialists Business Wire

Sep 27, 2021

07:39AM EDT Aerie Pharmaceuticals To Participate In The Cantor Global Healthcare Conference Benzinga

Sep 21, 2021

08:20AM EDT The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data Benzinga

07:19AM EDT The Bedminster-headquartered Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company, on Tuesday announced the appointment of Benjamin McGraw, III, as its interim Executive Chairman of the Board of Directors, to replace Vicente Anido, who resigned as Chairman and CEO on September 17. RTTNews

06:41AM EDT Aerie Pharmaceuticals Announces Departure Of Chairman And CEO Vicente Anido Benzinga

06:36AM EDT Aerie Pharma Appoints Benjamin McGraw As Interim Executive Chairman RTTNews

06:30AM EDT Aerie Pharmaceuticals, Inc. Announces the Appointment of Interim Executive Chair and Departure of Chairman and CEO Business Wire

Sep 20, 2021

06:34AM EDT Aerie Pharma Names Erik Pacyniak Director, Toxicology And Drug Disposition RTTNews

06:30AM EDT Aerie Pharmaceuticals Announces Appointment of Erik Pacyniak, Ph.D., D.A.B.T., as Director, Toxicology and Drug Disposition Business Wire

Sep 16, 2021

02:46PM EDT Mid-Afternoon Market Update: Dow Falls 70 Points; Aerie Pharmaceuticals Shares Plunge Benzinga

12:38PM EDT Mid-Day Market Update: Gold Drops Over 2%; Leap Therapeutics Shares Jump Benzinga

10:21AM EDT Mid-Morning Market Update: Markets Down; US Retail Sales Unexpectedly Increase in August Benzinga

07:48AM EDT The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study Benzinga

05:59AM EDT Aerie Pharma Reports Mixed Bag On Phase 2 Dry Eye Trial Benzinga

Sep 15, 2021

04:03PM EDT Aerie Pharmaceuticals Announces Novel Dry Eye Product Candidate AR-15512 Ophthalmic Solution Achieved Statistical Significance Over Multiple Symptoms And Signs In Successful Phase 2b Clinical Study For The Treatment Of Dry Eye Disease Benzinga

04:01PM EDT Aerie Pharmaceuticals Announces Novel Dry Eye Product Candidate AR-15512 (TRPM8 Agonist) Ophthalmic Solution Achieved Statistical Significance Over Multiple Symptoms and Signs in Successful Phase 2b Clinical Study for the Treatment of Dry Eye Disease Business Wire

Sep 14, 2021

12:22PM EDT USPTO Site Shows Aerie Pharmaceuticals Granted Patent 'Compounds, compositions and methods for treatment of myopia' Benzinga

Sep 13, 2021

06:37AM EDT Aerie Pharma Appoints Carolyn McAuliffe, Senior Director, Communications RTTNews

06:30AM EDT Aerie Pharmaceuticals Announces Appointment of Carolyn McAuliffe, Senior Director, Communications Business Wire

Sep 7, 2021

07:30AM EDT Aerie Pharmaceuticals to Participate in Upcoming Investor Conferences Business Wire

06:38AM EDT Aerie Pharma Names Michael Bradley, Senior Director, Manufacturing RTTNews

06:30AM EDT Aerie Pharmaceuticals Announces Appointment of Michael Bradley, Senior Director, Manufacturing Business Wire

Aug 20, 2021

02:37PM EDT Looking into Aerie Pharmaceuticals's Return on Capital Employed Benzinga

Aug 12, 2021

07:30AM EDT Aerie Pharmaceuticals to Participate in the H.C. Wainwright Ophthalmology Conference Business Wire

Aug 5, 2021

07:05AM EDT Needham Maintains Buy on Aerie Pharmaceuticals, Lowers Price Target to $24 Benzinga

Aug 4, 2021

04:26PM EDT Aerie Pharmaceuticals Q2 EPS $(0.84) Misses $(0.64) Estimate, Sales $27.20M Beat $26.28M Estimate Benzinga

04:01PM EDT Aerie Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update Business Wire

07:52AM EDT The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings Benzinga

04:10AM EDT Earnings Scheduled For August 4, 2021 Benzinga

Aug 1, 2021

11:19AM EDT The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs Benzinga

Jul 28, 2021

07:30AM EDT Aerie Pharmaceuticals to Announce Second Quarter 2021 Financial Results and Host Conference Call on Wednesday, August 4, 2021 Business Wire

Jul 20, 2021

04:04PM EDT Aerie Pharmaceuticals Announces Presentation at the Ophthalmology Innovation Summit European Innovation Showcase Benzinga

Jul 15, 2021

06:30AM EDT Aerie Pharmaceuticals Announces Appointment of Leon J. Atencia, Director of Regulatory Affairs Business Wire

Jun 21, 2021

07:00AM EDT Aerie Pharmaceuticals Announces Appointment of Frank Estrada, Ed.D., as Director, Salesforce Training Business Wire

06:45AM EDT Aerie Pharmaceuticals to Participate in the Raymond James Human Health Innovation Conference - UPDATED RELEASE Business Wire

Jun 17, 2021

06:41AM EDT Aerie Completes Enrollment Of First Phase 3 Trial Of Netarsudil Ophthalmic Solution In Japan RTTNews

06:34AM EDT Aerie Pharma Completes Enrollment Of First Phase 3 Clinical Trial of Netarsudil Ophthalmic Solution In Japan RTTNews

06:30AM EDT Aerie Pharmaceuticals Completes Enrollment of its first Phase 3 Clinical Trial of Netarsudil Ophthalmic Solution in Japan Benzinga

Jun 15, 2021

07:30AM EDT Aerie Pharmaceuticals to Participate in the Raymond James Human Health Innovation Conference Business Wire

May 24, 2021

05:30PM EDT Aerie Pharma 8-K Shows Co. CFO, Secretary, Treasurer, Richard Rubino, To Resign; Co. Will Conduct Search To Fill Position Benzinga

May 6, 2021

07:30AM EDT Aerie Pharmaceuticals to Participate in the Bank of America Securities 2021 Healthcare Conference Business Wire

May 5, 2021

04:19PM EDT Aerie Pharmaceuticals Q1 EPS $(0.72) Misses $(0.68) Estimate, Sales $23.00M Beat $22.78M Estimate Benzinga

04:01PM EDT Aerie Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update Business Wire

07:43AM EDT The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues Benzinga

04:16AM EDT Earnings Scheduled For May 5, 2021 Benzinga

Apr 29, 2021

06:54AM EDT Aerie Pharma Highlights Completion Of Enrollment In Phase 2b Trial Of AR-15512 Ophthalmic Solution For Treatment Of Patients with Dry Eye Disease; Sees Topline Results In Q3'21 Benzinga

06:30AM EDT Aerie Pharmaceuticals Completes Enrollment of its Phase 2b Clinical Trial of AR-15512 (TRPM8 Agonist) Ophthalmic Solution for the Treatment of Patients with Dry Eye Disease Business Wire

Apr 28, 2021

07:30AM EDT Aerie Pharmaceuticals to Announce First Quarter 2021 Financial Results and Host Conference Call on Wednesday, May 5, 2021 Business Wire

06:30AM EDT Aerie Pharmaceuticals Announces Presentations at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting Business Wire

Apr 19, 2021

06:40AM EDT Aerie Pharma Gets Marketing Authorisation Of Roclanda 50 Mcg/ml + 200 Mcg/ml Eye Drops, Solutionin Great Britain RTTNews

06:35AM EDT Aerie Pharmaceuticals Receives Marketing Authorisation Of Roclanda 50 micrograms/ml + 200 micrograms/ml Eye Drops, Solution In Great Britain Benzinga

06:30AM EDT Aerie Pharmaceuticals Receives Marketing Authorisation of Roclanda(r) 50 micrograms/ml + 200 micrograms/ml Eye Drops, Solution (latanoprost + netarsudil) in Great Britain Business Wire

Apr 7, 2021

07:30AM EDT Aerie Pharmaceuticals to Participate in the 20th Annual Needham Virtual Healthcare Conference Business Wire

Mar 30, 2021

08:21AM EDT Aerie :Findings From Mouse Model Show Netarsudil Can Reverse Tissue stiffness And Fibrosis In Trabecular Meshwork RTTNews

08:07AM EDT Aerie Pharma Highlights Publication OF Peer-Reviewed Paper Evaluating Treatment Effect Of Netarsudil On Outflow Function In Steriod-Induced Glaucoma Benzinga

08:05AM EDT Aerie Pharmaceuticals Announces Publication of Peer-Reviewed Paper Evaluating the Treatment Effect of Netarsudil on Outflow Function in Steroid-Induced Glaucoma Business Wire

Mar 16, 2021

08:17AM EDT The Daily Biotech Pulse: Fulgent Nabs CDC Contract, Enzo Rallies, Solid Biosciences Releases Gene Therapy Data, Moderna Begins Pediatric Vaccine Study Benzinga

Mar 11, 2021

04:01PM EST Aerie Pharmaceuticals Announces Presentation at the Ophthalmology Innovation Summit Dry Eye Innovation Showcase Business Wire

07:30AM EST Aerie Pharmaceuticals to Participate in the Oppenheimer 31st Annual Virtual Healthcare Conference Business Wire

Mar 4, 2021

08:12AM EST The Daily Biotech Pulse: FDA Nod For Pfizer, Kiniksa Rises On Commercialization Pact With Regeneron, Bio-Techne To Buy Diagnostic Company Benzinga

Mar 2, 2021

08:01AM EST The Daily Biotech Pulse: Roxadustat Delay For FibroGen, AstraZeneca, Decision Day For KemPharm, NanoViricides Jumps On COVID-19 Drug Data Benzinga

Mar 1, 2021

10:59AM EST Looking Into Aerie Pharmaceuticals's Return On Capital Employed Benzinga

Feb 25, 2021

04:25PM EST Aerie Pharmaceuticals Q4 EPS $(0.79) Misses $(0.73) Estimate, Sales $24.68M Beat $22.36M Estimate Benzinga

04:02PM EST Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update Business Wire

08:08AM EST The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants Benzinga

04:03AM EST Earnings Scheduled For February 25, 2021 Benzinga

Feb 22, 2021

07:30AM EST Aerie Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences Business Wire

Feb 18, 2021

07:30AM EST Aerie Pharmaceuticals to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on Thursday, February 25, 2021 Business Wire

Jan 11, 2021

06:36AM EST Aerie Pharma: EC Grants Approval For Roclanda 0.02%/0.005% RTTNews

06:36AM EST Aerie Pharmaceuticals Receives European Commission Approval for Roclanda (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% Benzinga

Nov 13, 2020

06:54AM EST Aerie Pharma Gets Positive CHMP Opinion For Roclanda In European Union RTTNews

06:50AM EST Aerie Pharma Reports Received Positive CHMP Opinion For Roclanda In EU Benzinga

06:50AM EST Aerie Pharmaceuticals Receives Positive CHMP Opinion for Roclanda(r) in the European Union Business Wire

Nov 10, 2020

07:30AM EST Aerie Pharmaceuticals to Participate in the Stifel 2020 Virtual Healthcare Conference Business Wire

Nov 9, 2020

06:38AM EST HC Wainwright & Co. Maintains Buy on Aerie Pharmaceuticals, Lowers Price Target to $29 Benzinga

Nov 5, 2020

04:10PM EST Aerie Pharmaceuticals Q3 EPS $(0.86) Misses $(0.80) Estimate, Sales $20.08M Beat $19.71M Estimate Benzinga

04:01PM EST Aerie Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Update Business Wire

07:54AM EST The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping Benzinga

04:34AM EST Earnings Scheduled For November 5, 2020 Benzinga

Nov 1, 2020

09:40AM EST The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings Benzinga

Oct 29, 2020

06:48AM EDT Aerie Pharma Says Begins Phase 2b Trial Of AR-15512 Ophthalmic Solution For Dry Eye Disease RTTNews

06:31AM EDT Aerie Pharma Reports Initiation of Phase 2b Trial Of AR-15512 Ophthalmic Solution For Treatment Of Patients With Dry Eye Disease Benzinga

06:30AM EDT Aerie Pharmaceuticals Initiates Phase 2b Clinical Trial of AR-15512 (TRPM8 Agonist) Ophthalmic Solution for the Treatment of Patients with Dry Eye Disease Business Wire

Oct 28, 2020

06:18AM EDT Santen and Aerie Conclude Exclusive License Agreement for Rhopressa and Rocklatan in Japan and Several Other Asian Countries; Aerie Will Receive An Upfront Payment Of $50M, And Various Development And Sales Milestones Of Up To $99M Benzinga

03:25AM EDT Santen, Aerie Conclude License Agreement For Rhopressa And Rocklatan In Japan And Several Other Asian Countries RTTNews

03:00AM EDT Santen and Aerie Conclude Exclusive License Agreement for Rhopressa(r) and Rocklatan(r) in Japan and Several Other Asian Countries Business Wire

Oct 27, 2020

07:30AM EDT Aerie Pharmaceuticals to Announce Third Quarter 2020 Financial Results and Host Conference Call on Thursday, November 5, 2020 Business Wire

Oct 22, 2020

07:52AM EDT The Daily Biotech Pulse: FDA Vaccine Committee Meeting, Roche In $350M Deal for COVID-19 Treatment, Edwards Lifesciences Reports Q3 Beat Benzinga

Oct 21, 2020

08:04AM EDT The Daily Biotech Pulse: Prothena Progress In Parkinson's Disease Pipeline, Fast Track For Xeris, Biogen Earnings Benzinga

Oct 20, 2020

08:17AM EDT The Daily Biotech Pulse: Aptinyx Jumps On Positive Readout, Cara Executes Korsuva Licensing Deal, Cleveland BioLabs Rallies On Reverse Merger Benzinga

Oct 19, 2020

02:37PM EDT Mid-Afternoon Market Update: Dow Falls 250 Points; BioSpecifics Technologies Shares Spike Higher Benzinga

12:17PM EDT Mid-Day Market Update: Front Yard Residential Surges Following Buyout Deal; American Equity Shares Plunge Benzinga

11:28AM EDT Why Aerie Pharmaceuticals Is Trading Lower Today Benzinga

10:00AM EDT Benzinga's Top Upgrades, Downgrades For October 19, 2020 Benzinga

08:07AM EDT B of A Securities Downgrades Aerie Pharmaceuticals to Underperform, Announces $9 Price Target Benzinga

Sep 29, 2020

06:39AM EDT Aerie Pharmaceuticals Announces Acceptance Of Its Investigational New Drug Application For AR-15512 (TRPM8 Agonist) Eye Drop For Dry Eye Disease Benzinga

06:36AM EDT Aerie Pharma Announces Acceptance Of IND Application For AR-15512 Eye Drop For Dry Eye Disease RTTNews

06:30AM EDT Aerie Pharmaceuticals Announces Acceptance of Its Investigational New Drug Application for AR-15512 (TRPM8 Agonist) Eye Drop for Dry Eye Disease Business Wire

Sep 24, 2020

06:43AM EDT Aerie Reports Successful Interim 90-day Topline Data From 6-month Phase 3b Clinical Trial In Europe Known As Mercury 3 RTTNews

06:31AM EDT Aerie Pharmaceuticals Announces Roclanda Achieves Non-Inferiority to Ganfort; Mercury 3 Performance Exceeds Prior Phase 3 Trials Benzinga

06:30AM EDT Aerie Pharmaceuticals Announces Successful Interim 90-Day Topline Data From Its Six-Month Mercury 3 Clinical Trial in Europe Business Wire

Sep 15, 2020

06:50AM EDT Aerie Pharma Sterile Fill Production Facility In Athlone Gets Approval From FDA For Production Of Rhopressa 0.02% RTTNews

06:46AM EDT Aerie Pharmaceuticals Announces FDA Approval Of Athlone, Ireland Facility For Production Of Rhopressa 0.02% Benzinga

06:45AM EDT Aerie Pharmaceuticals Announces U.S. Food and Drug Administration Approval of its Athlone, Ireland Facility for Production of Rhopressa(r) (netarsudil ophthalmic solution) 0.02% Business Wire

Sep 8, 2020

11:35AM EDT Guggenheim Initiates Coverage On Aerie Pharmaceuticals with Buy Rating, Announces Price Target of $20 Benzinga

07:30AM EDT Aerie Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences Business Wire

Aug 10, 2020

06:50AM EDT Citigroup Maintains Buy on Aerie Pharmaceuticals, Lowers Price Target to $32 Benzinga

Aug 7, 2020

06:34AM EDT Needham Maintains Buy on Aerie Pharmaceuticals, Lowers Price Target to $26 Benzinga

Aug 6, 2020

04:20PM EDT Aerie Pharmaceuticals Q2 EPS $(0.83) Misses $(0.80) Estimate, Sales $18.03M Beat $17.45M Estimate Benzinga

04:01PM EDT Aerie Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Business Update Business Wire

Jul 30, 2020

07:30AM EDT Aerie Pharmaceuticals to Announce Second Quarter 2020 Financial Results and Host Conference Call on Thursday, August 6, 2020 Business Wire

Jul 27, 2020

06:41AM EDT Aerie Reports Positive Topline Results For Phase 2 Clinical Trial Evaluating AR-1105 RTTNews

06:31AM EDT Aerie Pharmaceuticals Reports Topline Results for its AR-1105 Phase 2 Clinical Trial in Patients with Macular Edema Due to Retinal Vein Occlusio Benzinga

06:30AM EDT Aerie Pharmaceuticals Reports Positive Topline Results for AR-1105 (Dexamethasone Intravitreal Implant) Phase 2 Clinical Trial in Patients with Macular Edema Due to Retinal Vein Occlusion Business Wire

Share